| Robert Joseph Farrell Iv, MD | |
|
4359 New Shepherdsville Rd, Bardstown, KY 40004-8000 | |
| (502) 350-5492 | |
| (502) 350-5495 |
| Full Name | Robert Joseph Farrell Iv |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 21 Years |
| Location | 4359 New Shepherdsville Rd, Bardstown, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245433051 | NPI | - | NPPES |
| 2008-00427 | Other | NC | STATE LICENSE |
| 7100087210 | Medicaid | KY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Louisville | Louisville, KY | Hospital |
| Hardin Memorial Hospital | Elizabethtown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Family-level preventive intervention can lead to improved behavioral health outcomes for military families affected by wartime deployment, a new study published in the January 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports.
Process Systems Enterprise (PSE), providers of the world-leading gPROMS high-fidelity process modelling environment and related ModelCare services, launched its new gPROMS Solids product at this week's annual meeting of the International Fine Particles Research Institute (IFPRI) in Spa, Belgium.
BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.
› Verified 4 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Family-level preventive intervention can lead to improved behavioral health outcomes for military families affected by wartime deployment, a new study published in the January 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports.
Process Systems Enterprise (PSE), providers of the world-leading gPROMS high-fidelity process modelling environment and related ModelCare services, launched its new gPROMS Solids product at this week's annual meeting of the International Fine Particles Research Institute (IFPRI) in Spa, Belgium.
BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.
› Verified 4 days ago
| Entity Name | Commonwealth Specialists Of Kentucky Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770741498 PECOS PAC ID: 2466519673 Enrollment ID: O20090314000022 |
News Archive
Family-level preventive intervention can lead to improved behavioral health outcomes for military families affected by wartime deployment, a new study published in the January 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports.
Process Systems Enterprise (PSE), providers of the world-leading gPROMS high-fidelity process modelling environment and related ModelCare services, launched its new gPROMS Solids product at this week's annual meeting of the International Fine Particles Research Institute (IFPRI) in Spa, Belgium.
BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Joseph Farrell Iv, MD Po Box 936, London, KY 40743-0936 Ph: (606) 330-7818 | Robert Joseph Farrell Iv, MD 4359 New Shepherdsville Rd, Bardstown, KY 40004-8000 Ph: (502) 350-5492 |
News Archive
Family-level preventive intervention can lead to improved behavioral health outcomes for military families affected by wartime deployment, a new study published in the January 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports.
Process Systems Enterprise (PSE), providers of the world-leading gPROMS high-fidelity process modelling environment and related ModelCare services, launched its new gPROMS Solids product at this week's annual meeting of the International Fine Particles Research Institute (IFPRI) in Spa, Belgium.
BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.
› Verified 4 days ago
Richard C. Montgomery, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4371 New Shepherdsville Rd Unit 100, Bardstown, KY 40004 Phone: 502-350-5492 Fax: 502-350-5822 | |
Dr. Timothy A Jones, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4371 New Shepherdsville Rd Unit 100, Bardstown, KY 40004 Phone: 502-350-5492 Fax: 502-350-5822 | |
Dr. Mickey Dale Anderson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 118 Patriot Dr, Suite 203, Bardstown, KY 40004 Phone: 502-348-5588 Fax: 502-348-1046 |